Stockscreener 앱 받기
99.98
0.80%
0.79
시간 외 거래:
99.98
전일 마감가:
$99.19
열려 있는:
$100.03
하루 거래량:
360.75K
Relative Volume:
0.49
시가총액:
$6.43B
수익:
$74.06M
순이익/손실:
$-114.71M
주가수익비율:
-55.42
EPS:
-1.8039
순현금흐름:
$-117.90M
1주 성능:
+1.64%
1개월 성능:
-0.02%
6개월 성능:
+11.00%
1년 성능:
+118.97%
1일 변동 폭
$97.93
$100.80
1주일 범위
$97.93
$103.43
52주 변동 폭
$45.28
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
99.98 | 6.38B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Discipline and Rules-Based Execution in PTGX Response - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat
PTGX News | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating - Investing.com India
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa
Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
HC Wainwright Issues Positive Outlook for PTGX Earnings - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
A Look At Protagonist Therapeutics (PTGX) Valuation After First Quarter Earnings Swing To Profit - Sahm
Protagonist Therapeutics, Inc. $PTGX Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Protagonist Therapeutics Strengthens Market Buzz On Nasdaq Composite - Kalkine Media
This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year - simplywall.st
AIHC Capital Management Ltd Buys New Shares in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Behavioral Patterns of PTGX and Institutional Flows - Stock Traders Daily
(SEC Amendment) Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise By Investing.com - Investing.com Australia
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise - Investing.com UK
PTGX (NASDAQ: PTGX) CEO sells 75K shares under 10b5-1 trading plan - Stock Titan
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $113 - Moomoo
Protagonist Therapeutics Insider Sold Shares Worth $7,509,000, According to a Recent SEC Filing - Moomoo
Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares - Investing.com Nigeria
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares By Investing.com - Investing.com South Africa
Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M - TradingView
Protagonist Therapeutics (NASDAQ: PTGX) CEO sells 75,000 shares after exercising options - Stock Titan
75,000-share sale notice filed by PTGX insider (NASDAQ: PTGX) - Stock Titan
State Street Holds 3.12M Protagonist Therapeutics Shares (PTGX) - Stock Titan
Insiders At Protagonist Therapeutics Sold US$11m In Stock, Alluding To Potential Weakness - Moomoo
Protagonist Therapeutics Insider Sold Shares Worth $5,918,880, According to a Recent SEC Filing - Moomoo
Protagonist Therapeutics(PTGX.US) Director Sells US$5.92 Million in Common Stock - Moomoo
Protagonist Therapeutics director Giraudo sells $5.9m in shares By Investing.com - Investing.com Australia
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 36,000 Shares of Stock - MarketBeat
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan
Protagonist Therapeutics director Giraudo sells $5.9m in shares - Investing.com
Protagonist Therapeutics Director Sold Shares Worth Over $5.9M - TradingView
BMO reiterates Protagonist Therapeutics stock rating on launch momentum - Investing.com India
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):